From the Guidelines
Imatrex, also known as Sumatriptan, is classified as a 5-HT 1 receptor-specific agonist, commonly referred to as a triptan 1.
Key Characteristics of Triptans
- They are a widely prescribed and effective class of medications for migraines
- Usually reserved for use in patients with moderate to severe migraines or mild to moderate migraines that are unresponsive to analgesics or NSAIDs
- As a class, triptans are usually well tolerated, but contraindications to their use include ischemic vascular conditions, vasospastic coronary disease, uncontrolled hypertension, or other significant cardiovascular disease 1.
Specifics of Sumatriptan (Imitrex)
- Subcutaneously injectable sumatriptan reaches peak blood concentrations faster than any other migraine-specific medications (in approximately 15 minutes)
- Has been shown to be effective in 70 to 82 percent of patients
- Available in subcutaneous or intranasal form, which may be beneficial for patients with significant nausea and/or vomiting 1.
From the Research
Classification of Imatrex (Sumatriptan)
There is no information available in the provided studies to classify Imatrex (Sumatriptan) as it is not mentioned in any of the studies.
Available Information
The studies provided are related to Methotrexate, a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis (RA) 2, 3, 4, 5, 6.
Key Points
- Methotrexate is considered the preferred DMARD for the treatment of RA 2, 3, 4, 5, 6.
- The efficacy of methotrexate is comparable to biologic agents in parallel clinical trials of DMARD-naïve patients 3.
- Methotrexate monotherapy or combinations with other non-biologic DMARDs are effective in controlling disease activity in RA patients 4, 6.
- Methotrexate is a safe agent when used for years, provided that treatment is regularly monitored and prescribers follow some simple rules 5.
Note: There are no research papers to assist in answering the question about the classification of Imatrex (Sumatriptan).